Skip to content
Federal Budget, Medical Health Aged Care

ANZGOG welcomes the Federal Budget’s investment in medical research and clinical trials and highlights the need for continued focus on gynaecological cancers

Australia New Zealand Gynaecological Oncology Group (ANZGOG) 2 mins read

MEDIA RELEASE 
FOR IMMEDIATE RELEASE 

 

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) welcomes key initiatives in the Federal Budget that will support Australians living with gynaecological cancer. This includes investment in medical research, clinical trials, Pharmaceutical Benefits Scheme (PBS), Medicare and support for our healthcare workers. 

 

ANZGOG acknowledges the Federal Government’s commitment of $158.6 million over five years to support medical research and the translation of research into clinical practice, alongside the $150.3 million investment in expanding precision oncology programs, including the Australian Rare Cancers Portal. These investments represent a positive step in strengthening Australia’s healthcare system and advancing cancer care. 

 

However, with 19 women diagnosed with a gynaecological cancer every day, and more than half facing a rare or less common cancer with limited treatment options and poor survival rates, ANZGOG recognises the critical need for increased investment and collaboration in this area to change treatment, catalyse research and save women’s lives. 

 

ANZGOG Chair, Professor Clare Scott AM, said the organisation is committed to working with government and the broader health sector to ensure women with gynaecological cancers receive the same level of research investment and treatment innovation as those diagnosed with other cancers. 

 

"With the number of Australian women impacted by gynaecological cancer rising, it is essential that we continue to strengthen research and clinical trial investment to drive better outcomes. ANZGOG stands ready to collaborate with government, the health sector, and research partners to support, connect and implement these important initiatives." 

 

ANZGOG looks forward to working with the Federal Government to build on these Budget measures, as well as partnering with the Medical Research Future Fund, the Australian Cancer Plan, and the National Framework for Genomics in Cancer Control.   

 

Through targeted investment and transformative research, we can improve the diagnosis, treatment, and care of gynaecological cancers—delivering better outcomes for all those affected. - ENDS - 


About us:

About ANZGOG: The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation in Australia and New Zealand. Our vision is: Advancing research, Saving Lives. The group has more than 1500 members representing clinical, allied health and pure research specialties, and includes community. ANZGOG clinical trials are conducted at over 80 hospital sites and include both local and global collaborations to ensure the best research is available to improve life for women with a gynaecological cancer. 


Contact details:

Media inquiries: Monique Cerreto T: 0416 282 464 E: [email protected]  

More from this category

  • Medical Health Aged Care
  • 18/04/2025
  • 07:00
Monash University

Experts warn of increased alcohol harms over the Easter long weekend

Heavy alcohol consumption is usually associated with the summer months, not with Easter. But new analysis of Victorian ambulance data shows that there are regularly more than 500 alcohol-related attendances over the Easter long weekend. This heightened level of alcohol harm means the upcoming four-day weekend is the equivalent of four successive Saturday nights, and Victorians should consider their alcohol consumption and plan to stay safe as they prepare for Easter. The analysis reaffirms the findings of other projects led by the National Ambulance Surveillance System (NASS) at Turning Point and Monash University. VicHealth-funded research into the 2022 calendar year…

  • Contains:
  • Medical Health Aged Care
  • 17/04/2025
  • 23:26
Avania

Avania Strengthens Leadership Team With Pivotal Executive Appointments

BILTHOVEN, Netherlands & BOSTON–BUSINESS WIRE– Avania — the leading global MedTech advisory and clinical development partner — today announced the appointments of Jasmine Saba…

  • Contains:
  • Medical Health Aged Care
  • 17/04/2025
  • 22:11
Tilray Brands, Inc.

Tilray Medical Introduces Cannabis Edibles in Australia

Tilray Medical Expands Offerings with Good Supply Brand Medical Cannabis Pastilles for Australian PatientsSYDNEY, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.Denise Faltischek, Chief Strategy Officer and Head of…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.